Can you provide the last earnings date for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) last reported earnings on 3/31/2026.
NOVABAY PHARMACEUTICALS INC (NBY) Earnings History & Surprises
NYSEARCA:NBY • US66987P4090
Current stock price
1.95 USD
+0.36 (+22.64%)
At close:
1.98 USD
+0.03 (+1.54%)
After Hours:
NBY Earnings overview
Past quarterly earnings results for NOVABAY PHARMACEUTICALS INC (NBY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 13, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.20
- Revenue Estimate
- 3.636M
Last Reported
Most Recent- Release Date
- Mar 31, 2026
- Period
- Q4 / 2025
- EPS Reported
- EPS Surprise
- %
- Revenue Surprise
- -100.00%
Beat Rate
Last 8 Quarters 0%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.20 | - | -81.82% | 3.03M | -100.00% | -100.00% | ||
| Q3 2025 | -0.21 | - | 87.15% | 521K | 3.03M | -82.81% | -78.66% | |
| Q2 2025 | -0.21 | - | 96.90% | 3.03M | -100.00% | -100.00% | ||
| Q1 2025 | -0.24 | - | 99.08% | 3.03M | - | 15.17% | ||
| Q4 2024 | -0.11 | - | 99.95% | 2.309M | 3.184M | -27.48% | -38.05% | |
| Q3 2024 | -1.65 | -1.54 | -7.13% | 97.45% | 2.441M | 2.649M | -7.85% | -25.24% |
| Q2 2024 | -6.85 | -6.19 | -10.73% | 93.88% | 2.4M | 3.186M | -24.67% | -47.94% |
| Q1 2024 | -26.25 | -26.51 | 0.99% | 82.35% | 2.631M | 3.314M | -20.61% | -15.78% |
| Q4 2023 | -232.75 | -53.03 | -338.94% | -70.51% | 3.727M | 3.434M | 8.53% | 2.39% |
| Q3 2023 | -64.75 | -71.32 | 9.21% | 89.43% | 3.265M | 3.582M | -8.85% | -14.75% |
| Q2 2023 | -112.00 | -98.10 | -14.17% | 54.29% | 4.61M | 3.712M | 24.19% | 25.96% |
| Q1 2023 | -148.75 | -160.84 | 7.52% | 51.43% | 3.124M | 3.232M | -3.34% | -4.46% |
| Q4 2022 | -136.50 | -30.05 | -354.28% | -11.43% | 3.64M | 5.151M | -29.33% | 37.88% |
| Q3 2022 | -612.50 | -216.52 | -182.89% | -100.00% | 3.83M | 3.788M | 1.11% | 68.72% |
| Q2 2022 | -245.00 | -216.52 | -13.15% | - | 3.66M | 3.545M | 3.24% | 23.65% |
| Q1 2022 | -306.25 | -185.59 | -65.02% | -25.00% | 3.27M | 3.293M | -0.70% | 80.66% |
| Q4 2021 | -122.50 | -309.31 | 60.40% | 50.00% | 2.64M | 3.378M | -21.85% | 39.68% |
| Q3 2021 | -306.25 | -247.45 | -23.76% | 37.50% | 2.27M | 2.459M | -7.69% | 4.61% |
| Q2 2021 | -245.00 | -247.45 | 0.99% | 73.33% | 2.96M | 2.02M | 46.53% | -25.63% |
| Q1 2021 | -245.00 | -247.45 | 0.99% | 33.33% | 1.81M | 2.363M | -23.40% | -4.23% |
| Q4 2020 | -245.00 | -278.38 | 11.99% | - | 1.89M | 2.505M | -24.55% | - |
| Q3 2020 | -490.00 | -247.45 | -98.02% | - | 2.17M | 2.55M | -14.90% | - |
| Q2 2020 | -918.75 | -340.24 | -170.03% | - | 3.98M | 2.879M | 38.24% | - |
| Q1 2020 | -367.50 | -433.04 | 15.13% | - | 1.89M | 2.116M | -10.68% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
N/A
Average EPS beat (4)
N/A
Max EPS beat (4)
N/A
Min EPS beat (4)
N/A
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
Related analysis
NOVABAY PHARMACEUTICALS INC / NBY Earnings FAQ
Did NOVABAY PHARMACEUTICALS INC (NBY) beat earnings estimates last quarter?
NOVABAY PHARMACEUTICALS INC (NBY) missed EPS estimates and missed revenue estimates in the most recent quarter.